biphasic insulin aspart 30 + sitagliptin + metformin

This is a combination drug consisting of **biphasic insulin aspart 30**, **sitagliptin**, and **metformin**. It is used for the management of type 2 diabetes mellitus in adults, particularly in patients whose glycemic control is inadequate with oral agents alone. - **Biphasic insulin aspart 30** is an injectable insulin formulation containing 30% rapid-acting insulin aspart and 70% protaminated (intermediate-acting) insulin aspart. It helps lower blood glucose by promoting cellular uptake of glucose and inhibiting hepatic glucose production. - **Sitagliptin** is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin hormones, leading to increased insulin secretion and decreased glucagon secretion in a glucose-dependent manner[2][3][5]. - **Metformin** is a biguanide that decreases hepatic glucose production and improves insulin sensitivity[1][2][3]. The combination aims to provide comprehensive glycemic control by addressing insulin deficiency, insulin resistance, and impaired incretin activity[1][5][6].